Abstract
Type-2 innate lymphoid cells (ILC2) are a prominent source of type II cytokines and are found constitutively at mucosal surfaces and in visceral adipose tissue. Despite their role in limiting obesity, how ILC2s respond to high fat feeding is poorly understood, and their direct influence on the development of atherosclerosis has not been explored. Here, we show that ILC2 are present in para-aortic adipose tissue and lymph nodes and display an inflammatory-like phenotype atypical of adipose resident ILC2. High fat feeding alters both the number of ILC2 and their type II cytokine production. Selective genetic ablation of ILC2 in Ldlr−/− mice accelerates the development of atherosclerosis, which is prevented by reconstitution with wild type but not Il5−/− or Il13−/− ILC2. We conclude that ILC2 represent a major innate cell source of IL-5 and IL-13 required for mounting atheroprotective immunity, which can be altered by high fat diet.
Similar content being viewed by others
Introduction
Cardiovascular disease is the leading cause of death worldwide, increasing in incidence year on year and was accountable for one in four deaths globally in 2010 (ref. 1). Atherosclerosis is the major cause of cardiovascular disease where deposits of low-density lipoproteins in the arterial wall lead to the infiltration of immune cells, inflammation and growth of fibro-fatty plaques. This process can culminate in occlusion of the artery following plaque disruption and thrombosis2.
Plaque maturation is influenced by the populations of innate and adaptive immune cells infiltrating the lesion, their activation state and how they communicate with non-immune cells in the surrounding arterial tissue3,4,5. Hypercholesterolaemia and high fat diet (HFD) also trigger systemic immune responses that modulate the atherosclerotic process, which may explain the profound impact of spleen-dependent responses on several aspects of the atherosclerotic immune response6,7,8.
Innate lymphoid cells (ILC) are a rare cell population that are closely related to T and B lymphocytes, but which do not express recombined antigen receptors such as the T-cell receptor and B-cell receptor. Early research identified many different subtypes including conventional natural killer (NK) cells9, lymphoid tissue inducer cells10,11, nuocytes12 and natural helper cells13. ILC can be assigned to one of three groups, ILC1, ILC2 or ILC3 (ref. 14). These mirror the T helper (Th)1, Th2 and Th17 paradigm of T-cell biology and share effector cytokines and transcription factors. Th1 cells promote atherogenesis4, which is also the case for ILC1-related NK cells15. However, the impact of Th2 and Th17 bias on the atherosclerotic process is more complex; they may either enhance or limit the disease4,16.
ILC2 were initially identified as an innate source of IL-13 during helminth infection12. Subsequently they have been observed secreting large quantities of type II cytokines (IL-5, IL-13, IL-9), regulating innate and adaptive immune responses in several inflammatory settings (reviewed in ref. 17), modulating wound healing/tissue repair18, and influencing adipose tissue function and metabolic homeostasis19. Furthermore, there is growing evidence that some type II cytokines are protective in mouse models of atherosclerosis. For example, IL-13 has been shown to protect from lesion development and promote plaque stability by increasing collagen deposition, and skewing the macrophage infiltrate towards an alternative activated phenotype20. IL-5 on the other hand may be protective via increasing titres of natural IgM antibodies specific for modified LDL epitopes21. Finally, the atheroprotective cytokines IL-33 (ref. 22) and IL-25 (ref. 23) can drive expansion of ILC2 (refs 24) and these cells may provide a crucial component of the protective mechanism. However, IL33 and IL-25 activate may other cellular responses independently of ILC2, and type II cytokines are also secreted by other cell types and may act on atherosclerosis independently of ILC2.
Two recent studies suggested that ILC2 expansion in mice may have an athero-protective role23,26. However, the results were based on pharmacologic expansion of an ILC2 population, sometimes in immunodeficient mice, and were confounded by dramatic alterations in plasma cholesterol levels after treatment, or by alterations in other immune cell populations. Another study showed that total deficiency of Id3, which leads to increased atherosclerosis in mice, may reduce IL-5 production by ILC2 (after exogenous IL-33 stimulation)27. However, no direct relationship was provided to link the ILC2 and atherosclerosis phenotypes27. Thus, the role of naturally occurring ILC2 and the mechanisms through which they may regulate atherosclerosis are still unknown.
Thus, the focus of this work is in defining how ILC2 respond to hypercholesterolaemia, and how atherosclerosis develops in an environment where this cell type is absent. Our results show that ILC2 control the development of atherosclerosis, in part through production of type 2 cytokines.
Results
Characterization of ILC2 in atherosclerosis-prone mice
We first addressed the frequency of ILC2 in atherosclerosis-susceptible apolipoprotein e-deficient (Apoe−/−) mice fed normal chow diet. A typical overview of a transverse section of the aorta reveals several aortic and para-aortic structures (Supplementary Fig. 1A) where ILC2 may accumulate. Those structures include the atherosclerotic plaque, the aortic adventitia and associated tertiary lymphoid structures (ATLO), the para-aortic lymph nodes (PaLN), the para-aortic adipose tissue (PaAT) and fat-associated lymphoid clusters (FALCs). We therefore examined and quantified the presence of ILC2 in each of those structures using flow cytometry and immunofluorescence. Our analyses first revealed the presence of ILC2 (Lin− ICOS+ CD25+ CD127+) in PaLN and PaAT of chow-fed Apoe−/− mice (Fig. 1a), which is consistent with the previously reported presence of ILC2 in secondary lymphoid organs (GATA3+ICOS+CD3− cells in Supplementary Fig. 1B,C) and their tropism for adipose tissue (for example, peri-gonadal WAT) (Fig. 1a)28. The percentage of ILC2 among CD45+ cells in PaAT was smaller than in peri-gonadal WAT (Fig. 1b), but was substantially higher than the percentage of ILC2 in PaLN (Fig. 1b), and mesenteric lymph nodes (MLN) (Fig. 1b) of the same animals. Supplementary Fig. 1D shows the absolute number of ILC2 recovered from different locations in >20-week-old Apoe−/− mice.
The phenotype, activation state and function of ILC2 may change dependent on the tissue where they reside and the cytokine microenvironment29,30,31. We found that Lin−ICOS+ CD25+ CD127+ ILC2 of peri-gonadal WAT (GWAT) were mostly KLRG1+ST2+ (Fig. 1a,b) and were comparable to natural ILC2 (ref. 29), whereas ILC2 of MLN and PaLN were in large majority KLRG1+ST2− or ST2low (Fig. 1a,b), similar to a recently described population of inflammatory ILC2 with reduced ability to produce IL-5 and IL-13 (ref. 29). Interestingly, the ILC2 population in para-aortic fat differed significantly from that of peri-gonadal fat, and comprised a population expressing low amounts of ST2 on their surface (Fig. 1c). The number of PaAT ILC2 remained relatively constant during aging (Supplementary Fig. 1E). ILC2 were also found in ATLO of 80-week-old Apoe−/− mice with advanced atherosclerosis (Supplementary Fig. 2A,B).
Recent studies showed that inflammatory stimuli promote the formation of FALCs within WAT32. FALCs have been detected mostly in peri-gonadal, mesenteric and mediastinal WAT, with the pericardium accumulating a substantial number of clusters32. However, whether FALCs may also accumulate in the para-aortic region is still unknown. Given the role of inflammation in FALC formation, we reasoned that those clusters may be more prevalent in old animals (for example, 80 weeks). Indeed, we detected FALCs in the para-aortic WAT of both old WT and Apoe−/− mice (Fig. 1d,e, Supplementary Fig. 1A). As reported for other locations, para-aortic FALCs were rich in CD3+ T cells, B220+ B cells, CD138+ plasma cells (Fig. 1f), PNA+Ki67+ germinal centre-like B cells and Foxp3+ Tregs (Supplementary Fig. 2C), accumulated a few ILC2 (Fig. 1g), no follicular dendritic cells (CD35 staining in Fig. 1f) and were supplied with blood vessels, lymph vessels, high endothelial venules and ERTR7+ conduits (Supplementary Fig. 2C). The number and size of peri-aortic FALCs were significantly greater in Apoe−/− mice compared to WT mice (Fig. 1e), supporting a role for vascular inflammation in promoting para-aortic FALC formation.
Thus, besides their presence in WAT and secondary lymphoid organs, ILC2 are also present in para-aortic fat of athero-prone mice, where they display an inflammatory phenotype, distinct from the natural ILC2 phenotype of distant WAT and more similar to the inflammatory phenotype of lymph node ILC2.
High fat feeding alters ILC2 numbers and cytokine production
Mice fed a defined HFD for a period of weeks to months develop accelerated atherosclerosis. We therefore hypothesized that high fat feeding may alter the accumulation and function of ILC2 systemically, and observed the ILC2 populations in the bone marrow (BM), spleen and peripheral lymph nodes of low-density lipoprotein receptor-deficient (Ldlr−/−) mice, a second atherosclerosis-susceptible strain, that had been maintained on HFD for 8 weeks. Flow cytometric analysis of ILC2 populations (Fig. 2a) demonstrated that although there was no difference in the proportion of precursor cells in the BM (Fig. 2b), the mature ILC2 were significantly under-represented (2–3-fold loss) in MLN and PaLN of mice maintained on HFD (Fig. 2b).
To examine any change in functional capability associated with the suppression of this population, Lin− ICOS+ ILC2 cells were sorted from the spleens and MLN of conventional chow- and HFD-fed mice (purity>95%, Supplementary Fig. 2D). Not only were fewer cells recovered from the organs of HFD mice (Supplementary Fig. 2E and consistent with Fig. 2b) but, during ex-vivo expansion with IL-7 and IL-33, they also secreted substantially less IL-5 and IL-13 (Fig. 2c). To confirm that the alteration of type II cytokine production occurred in vivo, we repeated the experiments and performed QPCR analysis on cell-sorted ILC2 isolated from the spleens of Ldlr−/− mice that had been maintained on chow or HFD for 8 weeks. ILC2 were also cell-sorted from the aortas (two pools of three mice each) and GWAT for comparison (Fig. 2d). QPCR analysis indicated a significant decrease of GATA3 and IL-13 transcripts (Fig. 2d) and a similar trend observed with IL-5 (Fig. 2d), in spleen-derived ILC2 of mice on HFD compared to chow diet. Interestingly, GWAT-derived ILC2 showed no significant change, whereas aorta-derived ILC2 tended to upregulate their expression of GATA3, IL-5 and IL-13 after HFD (Fig. 2d). This is a strong indication that HFD differentially alters ILC2 phenotype in the periphery, and that continuous production of type II cytokines by aortic-ILC2 may be critical to maintain a counter-regulatory pathway, and limit the progression of aortic inflammation in face of a sharp decline of type II cytokine production by peripheral ILC2.
Expansion of ILC2 reduces atherogenesis
Similarly to others26, we hypothesized that reconstitution of ILC2 cells by treating with IL-2 during HFD would replenish an atheroprotective environment. To minimize off-target effects of IL-2 on other CD25-expressing cells such as Tregs, we used T- and B-cell-deficient Apoe−/−/Rag2−/− mice maintained on HFD for 8 weeks. The mice received three weekly injections of IL-2/Jes6-1 complex, which increases IL-2 biological activity33, for the duration of the experiment. Following this treatment, flow cytometry demonstrated ILC2 populations were significantly expanded in spleen and BM compared to PBS-treated controls (Fig. 3a). In addition to ILC2 expansion in peripheral lymphoid tissue, clusters of ICOS+ KLRG1+ (Fig. 3b) ILC2 cells were observed in the adventitia of the aorta adjacent to the aortic sinus by immunofluorescence. The adventitia has been suggested as a source of precursor cells, which may influence plaque architecture34 and the presence of expanded ILC2 in this tissue may suggest a direct localized effect. Whether these ILC2 have expanded in situ (as recent publications may suggest35) or have migrated into the tissue from the periphery remains to be investigated.
Further phenotypic changes occurred during this IL-2/Jes6-1 treatment, namely an expanded population of IL-5+ ILC2 (Lin− ICOS+), associated eosinophilia and decreased CD11b+ Ly6G− Ly6Chi inflammatory monocytes (Supplementary Fig. 3A). There was also an increase in splenic NK cells (Supplementary Fig. 3A). This treatment resulted in a significant decrease in the area of atherosclerotic plaques at the aortic sinus (Fig. 3c) and a similar trend was also observed at the aortic arch although this was not statistically significant. In contrast to a recent study where IL-2/Jes6-1 treatment of Ldlr−/−/Rag2−/− mice led to a substantial reduction of plasma VLDL-cholesterol levels26, our treatment of Apoe−/−/Rag2−/− mice with IL-2 was successful in reducing the effect of HFD on the progression of atherosclerosis, without any change in plasma lipid levels (Supplementary Fig. 3B). However, as reported in previous work26, IL-2 treatment was not without a number of off-target effects, the most common of which was an increase in splenic fibrosis in the IL-2 treated group, which was severe in some mice (Supplementary Fig. 3C). Additionally, weight gain upon HFD feeding was slower in the group receiving IL-2 compared to controls (Supplementary Fig. 3D).
Selective genetic ILC2 ablation exacerbates atherosclerosis
Artificial expansion of ILC2 does not inform about the true role of the endogenous ILC2 population that develops during the course of atherogenesis. To allow the specific depletion of ILC2 in an otherwise replete immune system, Staggerer/RorαFlox-Cd127Cre mice (which are selectively deficient in ILC2, hereafter known as ILC2KO (ref. 36)) were used as donors in a BM transplant model into atherosclerosis prone Ldlr−/− recipients. Given recent observations that in steady-state conditions tissue resident ILC2 are not replenished from circulating ILC2 (ref. 35), we validated the ability for BM ILC2 from Thy1.1 congenic mice to reconstitute lymphatic and tissue compartments. Thy1.2+ recipient mice were irradiated and reconstituted with Thy1.1+ BM. Following a 4-week recovery period, spleen, MLN and GWAT were collected and the proportion of Thy1.1+ donor ILC2 was determined by flow cytometry. We found that donor ILC2Thy1.1 fully reconstituted the lymphatic compartments (0% Thy1.2+ ILC2) as well as the majority of the GWAT tissue resident ILC2 (5% Thy1.2+) (Fig. 4a). Therefore, BM transplants are an effective method for replacing host with donor BM-derived ILC2. This was then repeated using either WT or ILC2KO BM followed by recovery and HFD for 9 weeks. To ensure the BM graft was effective and very few endogenous ILC2 remained, IL-33 was given to recipients 24 h before organ collection. Subsequent flow cytometry analysis demonstrated that recipients of ILC2KO BM had significantly decreased ILC2 in BM and peripheral MLN compared to ILC2WT recipients (Fig. 4b). Quantification of serum cytokines also demonstrated decreased IL-5 and IL-13 (Fig. 4c). Moreover, gene expression analysis on aorta and PaAT confirmed a substantial reduction of IL-5 and IL-13 expression in tissues recovered from ILC2KO mice (Fig. 4d). The extent of lipid accumulation in aortas of ILC2KO mice was significantly increased in the aortic arch (Fig. 4e) and aortic sinus (Fig. 4f) compared to ILC2WT recipients, despite no change in plasma lipid levels (Supplementary Fig. 4A).
As discussed above, ILC2 are a potent source of the type II cytokines IL-5 and IL-13, which are known to be atheroprotective through differing mechanisms. It was therefore logical to investigate whether the increase of disease severity in the ILC2KO model could be accounted for by deficiencies in these pathways. The potential expansion and maintenance of B1a B cells and associated increase in natural IgM antibodies by ILC2-derived IL-5 were investigated by flow cytometry in ILC2KO BM recipients. Although pooled results from a number of experiments suggested that B1a B cells were less abundant in the spleen and MLN of ILC2KO recipient mice (Supplementary Fig. 4B), there was considerable variation between biological replicates and not all repeats followed the same trend. Furthermore, there was no associated decrease in natural IgM isotypes in the serum of ILC2KO recipient mice after 8 weeks of HFD (Supplementary Fig. 4B) or difference in plaque IgM deposits (Supplementary Fig. 4C). Thus, changes in B1a B-cell subset are unlikely to account for the effect of ILC2 deletion on atherosclerosis although this remains to be clarified.
ILC2 alter plaque composition
To examine if ILC2 deletion impacts immune cell accumulation and activation in vivo, we analysed plaque composition. The number of CD3+ T cells in lesions of ILC2KO recipients was reduced (Supplementary Fig. 5A) indicating that the increase in lesion size was unlikely to be driven by T-cell activation. However, immune-fluorescent labelling of MOMA2+ myeloid cells in the aortic sinus revealed a larger lipid-containing core of foam cells in the absence of ILC2 (Fig. 5a). Interestingly, the expression of Arg1 was significantly decreased (Fig. 5b). There was no difference in the proportion of α-smooth muscle actin-expressing cells in plaques or the deposition of collagen throughout the plaque detected by Sirius red staining (Supplementary Fig. 5B). It is usual for larger, more advanced plaques in this model to contain more collagen deposits, and this absence of increased collagen deposition in the larger plaques of ILC2KO mice coupled with less Arg1 expression might indicate disrupted tissue repair mechanisms. The macrophage phenotype was therefore further investigated by flow cytometry. Here, we observed a significant decrease in CD11b+ F4/80+Arg1+ and CD11b+ F4/80+ Arg1+ iNOS+ macrophage population in the aorta and peri-aortic adipose tissue of ILC2KO mice and an expansion of CD11b+ F4/80+ iNOS+ macrophages (Fig. 5c). This shows that, although ILC2 are a rare population of cells, in mouse models of atherosclerosis they perform a critical role in preventing plaque development and their ablation alters macrophage phenotype and increases disease severity.
ILC2-derived IL-5 and IL-13 are required for atheroprotection
We designed reconstitution experiments to address the specific roles of ILC2-derived IL-5 or IL-13 in the control of atherosclerosis. BM transplantation experiments were performed in Ldlr−/− mice which received mixed BM transplants of ILC2WT, ILC2KO, 80% ILC2KO with 20% IL-5+ (ILC2-deficient mice reconstituted with IL-5 sufficient ILC2) or 80% ILC2KO with 20% IL-5KO (ILC2-deficient mice reconstituted with IL-5-deficient ILC2; 80% of all other cell types are still capable of IL-5 production). After recovery, mice were put on HFD for 8 weeks. Reproducing the original observation, ILC2KO mice showed increased atherosclerosis of the aortic arch (Fig. 6a). Additionally, ILC2KO mice reconstituted with IL-5+ ILC2 did not develop increased atherosclerosis compared to ILC2WT mice (Fig. 6a), further supporting the requirement for a competent ILC2 population to limit atherogenesis. Crucially however, recipients of ILC2KO/IL-5− BM, which are replete with IL-5-deficient ILC2, developed severe atherosclerosis comparable to the full ILC2 knockout condition (Fig. 6a). However, absence of ILC2-derived IL-5 did not alter lesion size in the aortic sinus (Supplementary Fig. 5C), suggesting the involvement of other pathways. Therefore, complementing the observations with ILC2 sourced IL-5, we examined the function of ILC2-derived IL-13 in a separate set of experiments by reconstituting BMT recipients with 80% ILC2KO and either 20% IL-13+ or 20% IL-13KO. As was observed with the ILC2-specific IL-5 deficiency, the inability of ILC2 to produce IL-13 significantly increased atherosclerosis in the aortic arch (Fig. 6a). Furthermore, there was a significant increase in lesion size in the aortic sinus of ILC2KO IL-13− recipients (Fig. 6b). Although no significant change in MOMA2+ expression was detected (Fig. 6c), Arg1 expression was decreased (Fig. 6c) as previously observed in ILC2KO recipients. We also found a significant reduction of collagen deposition in lesions of ILC2KO IL-13− recipients (Fig. 6d), indicating impaired vascular healing. ILC2-derived cytokines (IL-5 and IL-13) are therefore vital components controlling the progression of atherosclerosis, particularly IL-13 which may alter macrophage phenotype, and its absence leads to larger and potentially more vulnerable plaques.
Discussion
Here, we show that ILC2 constitute a major atheroprotective cell type. High fat feeding reduces the frequency of ILC2 in the periphery and profoundly alters their protective phenotype, concomitant with an acceleration of atherosclerosis. Using mice specifically deficient in ILC2, we show that endogenous ILC2 perform a central role in controlling the progression of atherosclerosis and this effect is in part dependent on ILC2-derived IL-5 and IL-13. Remarkably, production of IL-5 and IL-13 by other cell types is unable to compensate for the lack of those ILC2-derived cytokines, particularly IL-13, and their atheroprotective effects. IL-5-dependent atheroprotection was limited to the thoracic aorta and could not be attributed to changes in macrophage phenotype or B1-dependent natural IgM production. IL-13-dependent atheroprotection was associated with important changes in collagen deposition and macrophage phenotype, suggestive of alternative activation. However, the direct links between changes of macrophage phenotype and atheroprotection were not addressed. Future studies should try to understand the differential impact of HFD on peripheral versus aortic ILC2, and define their distinct contributions to limiting vascular inflammation and atherosclerotic lesion development.
Previous studies suggested a potential role for ILC2 in the modulation of atherosclerosis23,26. However, those studies used immune-compromised animals and relied on non-physiological exogenous and chronic administration of cytokines (that is, IL-2 and IL-25) that are not specific for the ILC2 population, and that can promote ILC2-independent immune responses. Moreover, those studies failed to provide any direct evidence of the involvement of ILC2 in atherosclerosis and were confounded by profound alterations of hepatic and lipid metabolism26 following chronic exogenous cytokine administration. We also found that chronic administration of IL-2/anti-IL2 complexes in immune-compromised animals reduced atherogenesis but in agreement with previous findings, the effect was associated with several adverse side effects. Most probably, the amount of IL-2/IL-2 mAb used in murine models is not physiologically relevant and further work is required to titrate the dose of cytokine required to protect against atherosclerosis without inducing undesirable side effects.
It is interesting to note, however, that low dose IL-2 therapy is reported to be safe in humans and has been successful in several clinical trials of immune-mediated diseases (reviewed in ref. 37) where exogenous IL-2 was used to expand Tregs. Remarkably, low-dose IL-2 in humans also increases the production of IL-5 (ref. 38) and this is attributed to the dose-dependent expansion of ILC2.
Thus, augmentation of ILC2 and ILC2-derived IL-5 or IL-13 on top of Treg expansion might constitute a potentially attractive double-hit therapy to limit accelerated atherosclerosis.
Methods
Mice
All work was conducted under UK Home Office project license regulations after approval by the Ethical Review Committee of the University of Cambridge.
Mice used in this investigation were Ldlr−/− (Jackson Labs 002207), Apoe−/−/Rag2−/− (Jackson Labs), and IL5−/− were from Manfred Kopj (ETH Zurich). IL-13gfp/gfp (ref. 12) and Staggerer/RorαFlox-CD127Cre mice were from A. McKenzie and H. Rodewald36,39. All mice were on the C57/Bl6 background apart from Thy1.1+ and Thy1.2+ mice which were Balb/c.
Bone marrow transplants
Eight-week-old female recipient mice were maintained over night with Baytril before irradiation with two doses of 5.5 Gy (separated by 4 h) followed by reconstitution with 1 × 107 sex-matched donor BM cells. Mice were then maintained on Baytril for a 4-week recovery period before organ collection (Thy1.1+/Thy1.2+) or fed either normal chow (SAFE diet 105) or Western High Fat Diet (Dietex, FAT 21%, Cholesterol 0.15%) for 8–9 weeks (ILC2KO, ILC2KO IL-5KO and ILC2KO and IL-13KO experiments).
In vivo ILC2 expansion
To expand ILC2 in Apoe−/−/Rag2−/−, IL-2 (Preprotech) was complexed with monoclonal antibody Jes6-1 (Bio legend #503701) at a ratio of 5:1, incubating at 37 °C for 30 min (ref. 40). Mice received 1 μg of complex IL-2 three times a week for 8 weeks. During this period mice were maintained on HFD (Western RD).
ILC2 isolation
The ILC2 population was expanded in mice with three daily injections of IL-33 (1 μg) intraperitoneally before spleens and lymph nodes were collected. Cell suspensions were prepared for flow sorting following standard protocols. ILC2 cells were sorted from the Lineage-negative ICOS-positive population and maintained in vitro. Ex vivo sorted ILC2 cells were plated at a density of 5 × 104 cells per well in RPMI (10% FCS Pen/Strep 50 μM 2-ME) supplemented with IL-7 and IL-33 (10 ng ml−1 each).
Molecular biology
RNA was extracted from ex vivo stimulated macrophages using RNEasy kit (Qiagen) following the manufacturer’s instructions followed by cDNA synthesis of 1 μg total RNA using (Qiagen). For ILC2KO BMT aorta and PaAT single cell suspensions were produced and RNA extracted using RNEasy micro+ kit (Qiagen) followed by cDNA synthesis using SMART v4 Ultra low input RNA kit (Clontec), with 11 cycles of PCR.
For ILC2 isolation and QPCR, 100 Lin− ICOS+ CD25+ ILC2 were directly sorted into SMART v4 lysis buffer (SMART v4 Ultra low input RNA kit, Clontec) and cDNA amplified as per instructions (14 cycles of PCR). For QPCR, a 1:50 dilution of cDNA pools was used with MESAGreen (Eurogentec) and cycled on a Lightcycler 480 (Roche). Primer sequences are as follows: GATA3 (For 5′-AAA GAA GGC ATC CAG ACC CG-3′ Rev 5′-TTG AAG GAG CTG CTC TTG GG-3′), IL-5 (For 5′-CAA GCA ATG AGA CGA TGA GGC-3′ Rev 5′-CCC ACG GAC AGT TTG ATT CTT C-3′), IL-13 (For 5′-TGT GTC TCT CCC TCT GAC CC-3′ Rev 5′-CAG GGC TAC ACA GAA CCC G-3′), Arg1 (For 5′-TGA AGA GCT GGC TGG TGT GGT-3′ Rev 5′-GCT TCC AAC TGC CAG ACT GTG GTC-3′), Fizz1 (For 5′-TCA AGG AAC TTC TTG CCA ATC-3′ Rev 5′-ACC CAG TAG CAG TCA TCC CAG-3′).
Flow cytometry
The following antibodies were used, brackets denote clone. Lineage cocktail comprises of CD3e (2c11), CD4 (RM4-5), CD19 (1D3), CD11b (M170) CD11c (N418) Gr1 (RB6-8C5) NK1.1 (PK136), FceRI (MAR-1) and Ter119, all FITC conjugated and used at a final concentration of 0.1 μg ml−1. ILC2 panel: ICOS-APC (C398.4A), ST2-e710 (RMST2-2), CD127 e450 (A7R34), CD25− Bv786 (3C7) KLRG1-PE Cy7 (2F1) were diluted to 0.2 μg ml−1 and incubated in the presence of 24G2 Fc receptor blocking. ILC2 were defined by flow cytometry as Lin− ICOS+ CD127+ CD25+ KLRG1+ ST2 variable. Macrophage phenotyping: CD11b+ F4/80+ Arg1+/iNOS+. CD11b-PE (M1/70 0.1 μg ml−1), F4/80 Pacific Blue (BM8 0.1 μg ml−1), iNOS Alexa647 (Polyclonal, Insight biotechnology 0.2 μg ml−1) Arginase-1 (Polyclonal N-20, Santa Cruz Biotechnology 0.2 μg ml−1), Chicken anti-Goat AF488 (ThermoFisher Scientific). Cells were washed and run on a LSR- Fortessa (BD Biosciences). Subsequent data were analysed with FloJo X analysis software (FreeStar Ashland, OR, USA).
Histology and immunohistochemistry and morphometry
Tissues were collected into 1% PFA overnight before washing into PBS. Quantification of atherosclerosis was performed using Oil red O staining as previously described41. Briefly, en face wholemount staining was performed on aorta cleaned of all peri-aortic adipose tissue and adventitia. A 0.5% working solution of Oil Red O (Sigma #O0625) dissolved in isopropyl alcohol was used, diluted to a working stock of 60% in distilled water. Aorta were rinsed with distilled water before a wash in 70% isopropyl alcohol. Whole aorta were immersed in working solution for 45 min followed by a wash in 70% isopropyl alcohol and 5 further washes in distilled water. For aortic sinus, OCT embedded frozen sections from PFA fixed hearts were air dried and washed in PBS followed by 60% isopropyl alcohol. Sections were then stained in freshly prepared Oil Red O working solution for 15 min, briefly washed in isopropyl alcohol before counterstaining with haematoxylin. Sections were then washed twice in Scott’s solution before mounting in aqueous mountant (CC/Mount, Sigma). Plaque collagen content was determined using Sirius Red staining under polarized light. Lesion size/collagen was quantified using Fiji42.
To delineate ATLOs and para-aortic FALCs, tissues were prepared as described5,43. Thus, 10 μm fresh frozen cross-sections were prepared and every tenth serial section at 100 μm intervals was stained with Oil Red O/haematoxylin and number of para-aortic lymphoid clusters and their sizes were quantified. Very small clusters (< 200 μm in size) and clusters around perivascular nerve and ganglia were discarded from morphometry analyses. Immunofluorescence staining was performed as previously described43, using marker antibodies. For ILC2 cells staining the following antibodies were used. Rabbit anti-human CD3e (F7.2.38, DAKO 2 μg ml−1), rat anti-mouse GATA3 (KT77, Abcam 2 μg ml−1), Armenian hamster anti-mouse ICOS (C398.4A, Biolegend 2 μg ml−1), rat IgG2a isotype for GATA3 (R35-95, BD, 2 μg ml−1) and Armenian hamster IgG Biotin (A19-3, BD, 2 μg ml−1). DAPI was used to stain DNA. Secondary antibodies were used as previously described44. For macrophage phenotype staining the following antibodies were used: MOMA2 (Abserotech MCA519G, 2 μg ml−1), rabbit anti mouse iNOS AF647 (Polyclonal, Insight biotechnology 5 μg ml−1), goat anti mouse Arginase-1(Polyclonal N-20, Santa Cruz 5 μg ml−1), and chicken anti goat AF488 (Thermofisher).
Cytokine quantification
In vitro expressed cytokine quantification was performed using IL-5 and IL-13 Duoset ELISA kit (R and D Systems) following the manufacturer’s instructions. Serum IL-5 and IL-13 were detected by enhanced sensitivity CBA FlexSet (BD Biosciences), diluted 1:20.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 4 software (Graph Pad Software, San Diego, CA, USA). An unpaired t-test was used to analyse parametric data sets whereas for non-parametric data the Mann–Whitney U-test was applied. Tests performed and calculated two-tailed P-values are indicated in the individual figure legends.
Data availability
The data that support the findings of this study are available from the corresponding author on reasonable request.
Additional information
How to cite this article: Newland, S. A. et al. Type-2 innate lymphoid cells control the development of atherosclerosis in mice. Nat. Commun. 8, 15781 doi: 10.1038/ncomms15781 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).
Libby, P. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. 368, 2004–2013 (2013).
Libby, P., Lichtman, A. H. & Hansson, G. K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38, 1092–1104 (2013).
Ait-Oufella, H., Sage, A. P., Mallat, Z. & Tedgui, A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ. Res. 114, 1640–1660 (2014).
Hu, D. et al. Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin beta receptors. Immunity 42, 1100–1115 (2015).
Caligiuri, G., Nicoletti, A., Poirier, B. & Hansson, G. K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109, 745–753 (2002).
Kyaw, T. et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 109, 830–840 (2011).
Robbins, C. S. et al. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 125, 364–374 (2012).
Kiessling, R., Klein, E., Pross, H. & Wigzell, H. ‘Natural’ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5, 117–121 (1975).
Mebius, R. E., Rennert, P. & Weissman, I. L. Developing lymph nodes collect CD4+CD3− LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 7, 493–504 (1997).
Kelly, K. A. & Scollay, R. Seeding of neonatal lymph nodes by T cells and identification of a novel population of CD3−CD4+ cells. Eur. J. Immunol. 22, 329–334 (1992).
Neill, D. R. et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464, 1367–1370 (2010).
Moro, K. et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463, 540–544 (2010).
Spits, H. et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145–149 (2013).
Li, Y. et al. CD4+ natural killer T cells potently augment aortic root atherosclerosis by perforin- and granzyme B-dependent cytotoxicity. Circ. Res. 116, 245–254 (2015).
Taleb, S., Tedgui, A. & Mallat, Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler. Thromb. Vasc. Biol. 35, 258–264 (2015).
Eberl, G., Colonna, M., Di Santo, J. P. & McKenzie, A. N. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science 348, aaa6566 (2015).
Rak, G. D. et al. IL-33-dependent group 2 innate lymphoid cells promote cutaneous wound healing. J. Invest. Dermatol. 136, 487–496 (2016).
Brestoff, J. R. et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519, 242–246 (2015).
Cardilo-Reis, L. et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol. Med. 4, 1072–1086 (2012).
Binder, C. J. et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114, 427–437 (2004).
Miller, A. M. et al. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339–346 (2008).
Mantani, P. T. et al. IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice. PLoS ONE 10, e0117255 (2015).
Fallon, P. G. et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med. 203, 1105–1116 (2006).
Hung, L. Y. et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc. Natl Acad. Sci. USA 110, 282–287 (2013).
Engelbertsen, D. et al. Expansion of CD25+ innate lymphoid cells reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 35, 2526–2535 (2015).
Perry, H. M. et al. Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler. Thromb. Vasc. Biol. 33, 2771–2779 (2013).
Molofsky, A. B. et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210, 535–549 (2013).
Huang, Y. et al. IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential ‘inflammatory' type 2 innate lymphoid cells. Nat. Immunol. 16, 161–169 (2015).
Molofsky, A. B. et al. Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 43, 161–174 (2015).
Moro, K. et al. Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17, 76–86 (2016).
Benezech, C. et al. Inflammation-induced formation of fat-associated lymphoid clusters. Nat. Immunol. 16, 819–828 (2015).
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924–1927 (2006).
Campbell, K. A. et al. Lymphocytes and the adventitial immune response in atherosclerosis. Circ. Res. 110, 889–900 (2012).
Gasteiger, G., Fan, X., Dikiy, S., Lee, S. Y. & Rudensky, A. Y. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981–985 (2015).
Oliphant, C. J. et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41, 283–295 (2014).
Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).
Van Gool, F. et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 124, 3572–3576 (2014).
Schlenner, S. M. et al. Fate mapping reveals separate origins of T cells and myeloid lineages in the thymus. Immunity 32, 426–436 (2010).
Polhill, T. et al. IL-2/IL-2Ab complexes induce regulatory T cell expansion and protect against proteinuric CKD. J. Am. Soc. Nephrol. 23, 1303–1308 (2012).
Sage, A. P. et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice—brief report. Arterioscler. Thromb. Vasc. Biol. 32, 1573–1576 (2012).
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
Grabner, R. et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J. Exp. Med. 206, 233–248 (2009).
Zhao, L. et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. 10, 966–973 (2004).
Acknowledgements
This research was supported by the Cambridge NIHR BRC Cell Phenotyping Hub. We thank Yuanfang Li (IPEK, LMU Munich) for para-aortic FALC morphometry. Funding bodies: British Heart Foundation RG/15/11/31593 and PG/15/99/31865 to Z.M.; ERC Starting Grant GA281164 to Z.M.; German Research Council YI 133/2-1 to C.Y.; HA 1083/15-4 to A.J.R.H.; and MO 3054/1-1 to S.M.
Author information
Authors and Affiliations
Contributions
S.A.N. contributed to the design of the experiments, conducted the experiments and was involved in writing the manuscript. S.M. and A.P.S. contributed to the design of the experiments and conducted the experiments. M.C., S.T., M.N., C.Y., D.H., L.L.K. and A.J.F. conducted the experiments. H.-R.R. contributed IL-7cre transgenic mice. J.A.W. and A.N.J.M. contributed to the design of the experiments, provided reagents and Rorαsg/fl IL7rCre mice. C.J.B. and A.J.H. contributed to the design of the experiments and provided reagents. Z.M. contributed to the design of the experiments and supervised and was involved in the writing of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
Supplementary Figures. (DOCX 11946 kb)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Newland, S., Mohanta, S., Clément, M. et al. Type-2 innate lymphoid cells control the development of atherosclerosis in mice. Nat Commun 8, 15781 (2017). https://doi.org/10.1038/ncomms15781
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/ncomms15781
This article is cited by
-
Sex differences exist in adult heart group 2 innate lymphoid cells
BMC Immunology (2022)
-
Liver group 2 innate lymphoid cells regulate blood glucose levels through IL-13 signaling and suppression of gluconeogenesis
Nature Communications (2022)
-
Metabolic control of innate lymphoid cells in health and disease
Nature Metabolism (2022)
-
The why and how of adaptive immune responses in ischemic cardiovascular disease
Nature Cardiovascular Research (2022)
-
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity
Nature Reviews Immunology (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.